Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

NCT05872724 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
DRUG: Chemoradiotherapy (small pelvic) + Zimberelimab

Sponsor

Suzhou Municipal Hospital